Denali–Sanofi Partnership Dosing Alzheimer’s Patients in DNL747 Clinical Trial

Denali–Sanofi Partnership Dosing Alzheimer’s Patients in DNL747 Clinical Trial
Denali Therapeutics has begun dosing patients in its Phase 1b clinical trial of DNL747 as a treatment for Alzheimer’s disease. “We are excited to advance DNL747 in a second neurodegeneration indication based on Phase 1 healthy volunteer data regarding DNL747’s safety profile, CNS [central nervous system] penetration, and target engagement, at the studied doses,” Carole Ho, MD, chief medical officer of Denali, said in a press release. DNL747 is a small molecular that was specifically designed to cross the blood brain barrier and inhibit a pro
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *